Zosano Pharma Corporation (NASDAQ:ZSAN) Cut to Strong Sell at ValuEngine

ValuEngine lowered shares of Zosano Pharma Corporation (NASDAQ:ZSAN) from a sell rating to a strong sell rating in a research report report published on Monday.

Shares of Zosano Pharma Corporation (ZSAN) traded down 2.8905% during trading on Monday, hitting $1.3304. 147,372 shares of the company were exchanged. The firm’s 50-day moving average price is $1.39 and its 200 day moving average price is $1.59. The firm’s market capitalization is $52.15 million. Zosano Pharma Corporation has a 12 month low of $0.45 and a 12 month high of $3.54.

Zosano Pharma Corporation (NASDAQ:ZSAN) last issued its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.04. On average, equities research analysts expect that Zosano Pharma Corporation will post ($0.97) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was reported by [[site]] and is the sole property of of [[site]]. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at [[permalink]].

In other Zosano Pharma Corporation news, CFO Georgia Erbez bought 68,000 shares of the stock in a transaction on Thursday, May 25th. The shares were bought at an average price of $1.32 per share, with a total value of $89,760.00. Following the purchase, the chief financial officer now directly owns 115,750 shares in the company, valued at approximately $152,790. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John Peter Walker bought 73,716 shares of the stock in a transaction on Thursday, May 25th. The shares were acquired at an average cost of $1.36 per share, for a total transaction of $100,253.76. Following the purchase, the chief executive officer now owns 169,344 shares in the company, valued at $230,307.84. The disclosure for this purchase can be found here. 2.95% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the company. Endurant Capital Management LP acquired a new stake in shares of Zosano Pharma Corporation during the first quarter valued at about $1,135,000. Nexthera Capital LP acquired a new stake in shares of Zosano Pharma Corporation during the first quarter valued at about $950,000. Perceptive Advisors LLC acquired a new stake in shares of Zosano Pharma Corporation during the first quarter valued at about $950,000. Victory Capital Management Inc. acquired a new stake in shares of Zosano Pharma Corporation during the first quarter valued at about $449,000. Finally, Granite Point Capital Management L.P. acquired a new stake in shares of Zosano Pharma Corporation during the first quarter valued at about $285,000. 24.03% of the stock is currently owned by institutional investors.

About Zosano Pharma Corporation

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

To view ValuEngine’s full report, visit ValuEngine’s official website.